Related Experiment Video
Updated: Mar 18, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Hypertension and Related Cardiovascular Disease Burden in China
1Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA.
Insights
Hypertension prevalence is rising in China, affecting over 335 million adults. Despite improved awareness and treatment, hypertension control remains critically low, posing a significant public health challenge.
Area of Science:
- Public Health
- Cardiology
- Epidemiology
Background:
- Cardiovascular diseases (CVDs) are the leading cause of death in China, driven by economic development, urbanization, and an aging population.
- Hypertension (HTN) is a major risk factor for CVDs, necessitating a thorough understanding of its status within the Chinese adult population.
Purpose of the Study:
- To conduct a comprehensive review of hypertension prevalence, awareness, treatment, and control in Chinese adults.
- To analyze trends in blood pressure (BP)-related morbidity and mortality of CVD over time in China.
Main Methods:
- Systematic review of existing studies and surveys on hypertension in China.
- Analysis of epidemiological data to assess prevalence, awareness, treatment, and control rates.
- Examination of geographic variations (north-south, urban-rural) in HTN metrics.
Main Results:
- Hypertension prevalence in Chinese adults is high and increasing, estimated at 33.6% (335.8 million people) in 2010.
- Awareness (33.4%) and treatment (23.9%) of HTN have improved, but control rates remain very low (3.9%) against a BP target of <140/90 mm Hg.
- Significant geographic disparities in HTN prevalence, awareness, treatment, and control exist across China.
Conclusions:
- Hypertension poses a substantial and growing threat to public health in China, with low control rates exacerbating CVD risks.
- Effective strategies are needed to improve HTN management and reduce BP-related morbidity and mortality.
- Developing and implementing practical, sustainable prevention and treatment strategies at national and local levels is crucial for China.
Background:
With rapid economic development, urbanization, and an aging population, cardiovascular diseases (CVDs) have become the leading cause of death in China.
Objectives:
The aim of this study was to provide a comprehensive review on the prevalence, awareness, treatment, and control of hypertension (HTN) as well as blood pressure (BP)-related morbidity and mortality of CVD in Chinese adults over time.
Findings:
The prevalence of HTN in China is high and increasing. Recent estimates are variable but indicate 33.6% (35.3% in men and 32% in women) or 335.8 million (178.6 million men and 157.2 million women) of the Chinese adult population had HTN in 2010, which represents a significant increase from previous surveys. BP-related CVD remains the leading cause of death in Chinese adults, with stroke being the predominant cause of cardiovascular deaths. Of those with HTN, 33.4% (30.4% in men and 36.7% in women) were aware of their condition, 23.9% (20.6% in men and 27.7% in women) were treated, and only 3.9% (3.5% in men and 4.3% in women) were controlled to the currently recommended target of BP <140/90 mm Hg. Awareness and treatment of HTN have improved over time, but HTN control has not. Geographic differences in the prevalence, awareness, treatment, and control of HTN are evident, both in terms of a north-south gradient and urban-rural disparity.
Conclusions:
The prevalence of HTN is high and increasing, while the control rate is low in Chinese adults. Combatting HTN and BP-related morbidity and mortality will require a comprehensive approach at national and local levels. The major challenge moving forward is to develop and implement effective, practical, and sustainable prevention and treatment strategies in China.
Related Concept Videos
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension IV: Drug Therapy and Lifestyle Modifications
Coronary Artery Disease I: Introduction

